MCI patients were further categorized into subgroups MCI+ (positive biomarker), MCI− (negative biomarker), and MCI unknown (biomarker status unknown) based on CSF tests for the beta-amyloid and tau biomarkers of AD neuropathology. This evidence concerns the gene MAPT and Alzheimer disease.